The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells-Reference-Cited by-同舟云学术

The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells

Published:2012-08 Issue:8 Volume:40 Page:634-645.e10
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

Amaru Calzada Ariel,Todoerti Katia,Donadoni Luca,Pellicioli Anna,Tuana Giacomo,Gatta Raffaella,Neri Antonino,Finazzi Guido,Mantovani Roberto,Rambaldi Alessandro,Introna Martino,Lombardi Luigia,Golay Josée

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference47 articles.

1. Myeloproliferative disorders;Levine;Blood,2008

2. Aberrant signal transduction pathways in myeloproliferative neoplasms;Kota;Leukemia,2008

3. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera;Ugo;Exp Hematol,2004

4. Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice;Tiedt;Blood,2008

5. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells;Mullally;Cancer Cell,2010

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging role of MYB transcription factors in cancer drug resistance;Cancer Drug Resistance;2024-04-30

2. Synthetic oleanane triterpenoids suppress MYB oncogene activity and sensitize T-cell acute lymphoblastic leukemia cells to chemotherapy;Frontiers in Oncology;2023-04-03

3. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies;Signal Transduction and Targeted Therapy;2023-02-17

4. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors;Advances in Cancer Research;2023

5. Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms;Cancers;2022-02-15